{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-048114","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2024-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.074169+00:00","generated_at":"2026-05-29T11:49:13.065988+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Senti Bio reports 2 of 3 AML patients achieve MRD-negative CR in Phase 1 SENTI-202 trial","bullets":["Two of three R/R AML patients at lowest dose (1.0B CAR+ NK cells) achieved CR with MRD negativity; both maintain remission (4+ and 3+ months).","SENTI-202 was generally well-tolerated with no DLTs; adverse events consistent with lymphodepleting chemotherapy and other investigational NK therapies.","Dose escalation continues at 1.5B cells/dose level; additional safety, efficacy and durability data expected in 2025.","SENTI-202 transgene detected in peripheral circulation of all patients across cycles, with PK profile similar to other CAR-NK therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-048114","json":"https://secwatch.observer/filing/0001140361-24-048114.json","markdown":"https://secwatch.observer/filing/0001140361-24-048114.md","text":"https://secwatch.observer/filing/0001140361-24-048114.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000114036124048114/0001140361-24-048114-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000114036124048114/ef20039399_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T11:49:13.065988+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}